Javascript must be enabled to continue!
Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis
View through CrossRef
BackgroundIn recent years, the vaccinia oncolytic virus has entered the clinical trial stage of examination and shown good progress. It has many advantages, such as good safety, high oncolytic efficiency, and the regulation ability of the tumor microenvironment, and is expected to be successfully used in the clinical treatment of tumors in the future. However, no bibliometric analysis has so far been performed that generalizes horizontally across this field. Therefore, this study aims to assess the research status and trends in this field from a global perspective to help guide future research priorities.MethodsIn this study, the literature related to vaccinia oncolytic virus published in English on Web of Science from 2002 to 2022 was retrieved, and the bibliometric indicators were analyzed using the Histcite. Pro 2.0 tool, while VOSviewer was used to visualize the research trends and hotspots in this field.ResultsIn total, 408 related studies were included. In the past 20 years, the number of related publications in this field has increased year by year, and breakthroughs were made in this field in 2008 and 2013. The research has grown rapidly since 2008, and will likely continue to expand in the years to come. The United States plays a leading role in this area. “MOLECULAR THERAPY-ONCOLYTICS”, “MOLECULAR THERAPY” and “JOURNAL OF TRANSLATIONAL MEDICINE” are core journals that publish high-quality literature on the latest advances in the field. Some authors with numerous high-quality publications include Bell JC and Szalay AA. At present, the research hotspot in this field focus on the clinical application of vaccinia oncolytic virus.ConclusionOverall, the number of vaccinia oncolytic virus-related studies is growing rapidly, in relation to which the United States is the most influential country. The clinical application of vaccinia oncolytic virus will affect the crucial development of future research.
Frontiers Media SA
Title: Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis
Description:
BackgroundIn recent years, the vaccinia oncolytic virus has entered the clinical trial stage of examination and shown good progress.
It has many advantages, such as good safety, high oncolytic efficiency, and the regulation ability of the tumor microenvironment, and is expected to be successfully used in the clinical treatment of tumors in the future.
However, no bibliometric analysis has so far been performed that generalizes horizontally across this field.
Therefore, this study aims to assess the research status and trends in this field from a global perspective to help guide future research priorities.
MethodsIn this study, the literature related to vaccinia oncolytic virus published in English on Web of Science from 2002 to 2022 was retrieved, and the bibliometric indicators were analyzed using the Histcite.
Pro 2.
0 tool, while VOSviewer was used to visualize the research trends and hotspots in this field.
ResultsIn total, 408 related studies were included.
In the past 20 years, the number of related publications in this field has increased year by year, and breakthroughs were made in this field in 2008 and 2013.
The research has grown rapidly since 2008, and will likely continue to expand in the years to come.
The United States plays a leading role in this area.
“MOLECULAR THERAPY-ONCOLYTICS”, “MOLECULAR THERAPY” and “JOURNAL OF TRANSLATIONAL MEDICINE” are core journals that publish high-quality literature on the latest advances in the field.
Some authors with numerous high-quality publications include Bell JC and Szalay AA.
At present, the research hotspot in this field focus on the clinical application of vaccinia oncolytic virus.
ConclusionOverall, the number of vaccinia oncolytic virus-related studies is growing rapidly, in relation to which the United States is the most influential country.
The clinical application of vaccinia oncolytic virus will affect the crucial development of future research.
Related Results
Oncolytic Vaccinia Virus Gene Therapy for HNSCC
Oncolytic Vaccinia Virus Gene Therapy for HNSCC
ProblemOncolytic viral therapy a promising new strategy for the treatment of cancer and an oncolytic adenovirus was first licensed for head and neck squamous cell carcinoma (HNSCC)...
Selective Killing of Vaccinia Virus by LL-37: Implications for Eczema Vaccinatum
Selective Killing of Vaccinia Virus by LL-37: Implications for Eczema Vaccinatum
Abstract
Possible bioterrorism with smallpox has led to the resumption of smallpox (vaccinia virus) immunization. One complication, eczema vaccinatum, occurs prim...
Monkeypox Vaccines: Current Update
Monkeypox Vaccines: Current Update
Monkeypox belonging to the genus Orthopoxvirus (OPV) of the family poxviridiae poses a major human threat even after 30 years after eradicating smallpox. OPV family includes other ...
Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma
Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma
Abstract
Malignant melanoma is aggressive cancer with a high rate of local invasiveness and metastasis. Currently, the treatment options for patients with advanced-stage an...
Oncolytic Virotherapy in Breast Cancer.
Oncolytic Virotherapy in Breast Cancer.
Breast cancer has a high incidence and fatality rate, making it a major worldwide health problem. Traditional treatment methods, treatments including chemotherapy, radiation therap...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Abstract 1734: In vivo immunomodulatory effects by uPAR-retargeted oncolytic Measles virus
Abstract 1734: In vivo immunomodulatory effects by uPAR-retargeted oncolytic Measles virus
Abstract
Background: Oncolytic viruses offer an advantage over other treatment options, as they both induce cytotoxicity as well as immune modulation. Oncolytic meas...

